Contineum Therapeutics Inc has a consensus price target of $28, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from Stifel, RBC Capital, and Morgan Stanley on April 30, 2024. With an average price target of $28 between Stifel, RBC Capital, and Morgan Stanley, there's an implied 75.00% upside for Contineum Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/30/2024 | Buy Now | 81.25% | Stifel | Paul Matteis | → $29 | Initiates | → Buy | Get Alert |
04/30/2024 | Buy Now | 87.5% | RBC Capital | Brian Abrahams | → $30 | Initiates | → Outperform | Get Alert |
04/30/2024 | Buy Now | 56.25% | Morgan Stanley | Jeffrey Hung | → $25 | Initiates | → Overweight | Get Alert |
The latest price target for Contineum Therapeutics (NASDAQ: CTNM) was reported by Stifel on April 30, 2024. The analyst firm set a price target for $29.00 expecting CTNM to rise to within 12 months (a possible 81.25% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Contineum Therapeutics (NASDAQ: CTNM) was provided by Stifel, and Contineum Therapeutics initiated their buy rating.
There is no last upgrade for Contineum Therapeutics.
There is no last downgrade for Contineum Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Contineum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Contineum Therapeutics was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.
While ratings are subjective and will change, the latest Contineum Therapeutics (CTNM) rating was a initiated with a price target of $0.00 to $29.00. The current price Contineum Therapeutics (CTNM) is trading at is $16.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.